COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Novel coronavirus infectious disease (COVID-19) has been recognised as a pandemic by the World Health Organization (WHO) [1]. Mortality and morbidity are higher in elderly individuals and those with comorbidities, such as diabetes mellitus (DM), obesity, hypertension, respiratory tract diseases, coronary heart disease or cancer [1]. Indeed, two thirds of individuals who died from COVID-19 had DM in Italy [2].

Importantly, Chen et al. [3] have demonstrated that COVID-19 may exert a significant deleterious effect on myocardium and cardiac function. Moreover, some patients with COVID-19 develop acute kidney injury (AKI), which carries a worse prognosis [4].

Given the importance of DM in the outcomes of COVID-19 [5], antidiabetic treatment options and the need to achieve adequate glycaemic control are increasingly being discussed [5, 6]. Of relevance, sodium-glucose cotransporter 2 inhibitors (SGLT-2is) are known to reduce cardiovascular events and to protect kidney function [7] in type 2 DM. Thus, it appears worth examining the potential effect of SGLT-2is on preventing and/or delaying the development of cardiovascular events and AKI in patients hospitalised with acute COVID-19, regardless of diabetes.

In this setting, two trials with dapagliflozin as a cardioprotective and renoprotective agent in COVID-19 have already been initiated: DARE-19 (Dapagliflozin in respiratory failure in patients with COVID-19) [8] and TACTIC-E (Multi-Arm therapeutic study in pre-ICU patients admitted with Covid-19 - experimental drugs and mechanisms) [9]. The rationale for these trials is that SGLT-2is not only improve heart failure and renal function in type 2 DM [7], but they also appear to reduce inflammation, hypoxia and excess cytokine release [10, 11]. Importantly, the latter is known to play a pivotal role in adverse outcomes in COVID-19 [12, 13]. In DARE-19 (900 participants), inclusion criteria are hospitalisation for mild-to-moderate COVID-19 (arterial oxygen saturation ≥ 94% with low-flow supplemental oxygen) of any duration and at least one of the following: hypertension; type 2 DM; atherosclerotic cardiovascular disease; heart failure; chronic kidney disease stage 3 to 4 [8]. Patients will be randomised (1:1:1) to dapagliflozin 10 mg daily or placebo for 30 days and followed up for a total of 60 days [8]. The primary endpoint will be time to first death from any cause or new/aggravated organ dysfunction [8]. In TACTIC-E, 1407 patients with COVID-19 without need for intensive care unit (ICU) will be enrolled [9]. These will be randomised (1:1:1) to either the experimental drug EDP1815 (preparation of a single strain of Prevotella histicola) or dapagliflozin 10 mg daily plus ambrisentan (endothelin receptor antagonist) or standard care alone [9]. The primary endpoint will be the composite end-point comprising death, mechanical ventilation, extracorporeal membrane oxygenation, cardiovascular support or renal failure [9]. In DARE-19 [8] and TACTIC-E [9], design and endpoints are based on the known renoprotective and cardioprotective properties of SGLT-2is [7, 11, 14] and on accepted meaningful parameters of COVID-19 clinical course [1–3].

Whether, indeed, SGLT-2is will prove beneficial in this new condition is currently a matter of investigation and hope. Potential helpful mechanisms include, among others, increased haematocrit, slight increase of ketone bodies, as well as reduction of endothelial dysfunction, glomerular hyperfiltration, oxidative stress and inflammation [9, 11, 14]. Certainly, caution is needed until we obtain tangible data on their utility or otherwise. However, unlike the Shakespearean hero, we should not lose potential benefits by “fearing to attempt” [15].

Funding
No funding or sponsorship was received for this study or publication of this article.

Conflict of Interest
NP has been an advisory board member of Astra-Zeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda and Trigocare International; has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSX, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for Astra-Zeneca, Boehringer Ingelheim, Eli-Lilly, Epen, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and attended conferences sponsored by Trigocare International, Eli-Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis. APS has given talks, attended conferences, and participated in advisory boards, and clinical trials sponsored by various pharmaceutical companies and she is currently Vice-President, National Diabetes Commission, Ministry of Health, Romania.

References

Papachristou S et al. COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors ... Exp Clin Endocrinol Diabetes | © 2020. Thieme. All rights reserved.


Packer M. Do sodium-glucose co-transporter 2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? Diabetes Obes Metab 2018; 20: 1361–1366


Authors
Stella Papachristou¹, Theano Penlioglou¹, Anca Pantea Stoian², Nikolaos Papanas³

Affiliations
1 Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
2 Diabetes, Nutrition and Metabolic Diseases Department, “Carol Davila” University of Medicine, Bucharest, Romania

Key words
diabetes, autoimmunity, COVID-19, SGLT-2 inhibitors, treatment

26.05.2020
02.08.2020
06.08.2020
2020

Correspondence
Prof. Nikolaos Papanas
Diabetes Centre
Second Department of Internal Medicine
Democritus University of Thrace
Alexandroupolis
Greece
Tel.: +30 25513 51723, Fax: +30 25513 51723
papanasnikos@yahoo.gr

Bibliography

Exp Clin Endocrinol Diabetes
DOI 10.1055/a-1235-5617
ISSN 0947-7349
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.